---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Drug interactions questions"
description: "Drug interactions questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can Biktarvy be taken with antacids or calcium, iron, or magnesium supplements? What drugs interact with Biktarvy? Does Biktarvy interact with birth control pills, sertraline, or sofosbuvir-based hepatitis C medicines? Can Biktarvy be taken with other HIV medicines? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Drug interactions questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Drug interactions

<a id="biktarvy-antacids-supplements"></a>

### Can Biktarvy be taken with antacids or calcium, iron, or magnesium supplements?

> “Oral medications or supplements containing polyvalent cations (eg, Mg, Al, Ca, Fe):
> Calcium or iron supplements<sup>†</sup>
> Cation-containing antacids or laxatives<sup>†</sup>
> Sucralfate
> Buffered medications
>
> Antacids containing Al/Mg:
>
> BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg.
>
> Routine administration of BIKTARVY together with, or 2 hours after, antacids containing Al/Mg is not recommended.
>
> Supplements or antacids containing Ca or Fe:
>
> BIKTARVY and supplements or antacids containing Ca or Fe can be taken together with food.
>
> Routine administration of BIKTARVY under fasting conditions together with, or 2 hours after, supplements or antacids containing Ca or Fe is not recommended.
>
> In pregnant individuals:
>
> Antacids containing Al/Mg:
>
> BIKTARVY can be taken at least 2 hours before or 6 hours after antacids containing Al/Mg regardless of food intake.
>
> Supplements or antacids containing Ca or Fe:
>
> BIKTARVY and supplements or antacids containing Ca or Fe can be taken together with food; but when taken on an empty stomach, BIKTARVY should be taken at least 2 hours before or 6 hours after supplements or antacids containing Ca or Fe.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=Oral%20medications%20or%20supplements%20containing,antacids%20containing%20Ca%20or%20Fe.)

<a id="biktarvy-drug-interactions"></a>

### What drugs interact with Biktarvy?

> “Established and potentially significant* drug interactions:
> (alteration in regimen may be recommended)
> Concomitant Drug Class: Drug Name
> Clinical Comment
>
> Antiarrhythmics:
> Dofetilide
>
> Coadministration is contraindicated due to the potential for serious and/or life-threatening events associated with dofetilide therapy.
>
> Anticonvulsants:
> Carbamazepine<sup>†</sup>
> Oxcarbazepine
> Phenobarbital
> Phenytoin
>
> Coadministration with alternative anticonvulsants should be considered.
>
> Antimycobacterials:
> Rifabutin<sup>†</sup>
> Rifampin<sup>†,‡</sup>
> Rifapentine
>
> Coadministration with rifampin is contraindicated due to the effect of rifampin on the BIC component of BIKTARVY.
>
> Coadministration with rifabutin or rifapentine is not recommended.
>
> Herbal products:
> St. John’s wort<sup>§</sup>
>
> Coadministration with St. John’s wort is not recommended.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=Established%20and%20potentially%20significant%2A%20drug,John%E2%80%99s%20wort%20is%20not%20recommended.)

> “*Table is not all-inclusive.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=%2ATable%20is%20not%20all%2Dinclusive.)

> “Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=Refer%20to%20the%20prescribing%20information,use%20of%20BIKTARVY%20and%20metformin.)

> “<sup>†</sup>Drug-drug interaction study was conducted with either BIKTARVY or its components as individual agents.
>
> <sup>‡</sup>Strong inducer of CYP3A and P-gp, and inducer of UGT1A1.
>
> <sup>§</sup>The induction potency of St. John’s wort may vary widely based on preparation.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=interaction%20study%20was%20conducted%20with,vary%20widely%20based%20on%20preparation.)

> “Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of BIKTARVY. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of BIKTARVY. BIKTARVY can increase the concentration of drugs that are substrates of OCT2 or MATE1.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Enzymes%2Ftransporters%3A%20Drugs%20that%20induce%20P%2Dgp,substrates%20of%20OCT2%20or%20MATE1.)

> “Drugs affecting renal function: Coadministration of BIKTARVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Drugs%20affecting%20renal%20function%3A%20Coadministration,the%20risk%20of%20adverse%20reactions.)

<a id="biktarvy-no-interaction-drugs"></a>

### Does Biktarvy interact with birth control pills, sertraline, or sofosbuvir-based hepatitis C medicines?

> “Based on drug interaction studies conducted with BIKTARVY or the components of 
> BIKTARVY, no clinically significant drug interactions have been observed when 
> BIKTARVY is combined with the following drugs: ethinyl estradiol, ledipasvir/sofosbuvir, 
> midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and 
> sofosbuvir/velpatasvir/voxilaprevir.”

Source: [BIKTARVY: Prescribing information, page 14, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=14)

<a id="biktarvy-other-hiv-medicines"></a>

### Can Biktarvy be taken with other HIV medicines?

> “Because BIKTARVY is a complete regimen, coadministration with other antiretroviral 
> medications for the treatment of HIV-1 infection is not recommended [see Indications 
> and Usage (1)]. Comprehensive information regarding potential drug-drug interactions 
> with other antiretroviral medications is not provided because the safety and efficacy of 
> concomitant HIV-1 antiretroviral therapy is unknown.”

Source: [BIKTARVY: Prescribing information, page 11, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=11)

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
